Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00267332 · ClinicalTrials.gov registry record · Phase 3

Modafinil in Opioid Induced Sedation

A Phase 3 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Terminated
Registry status
Phase 3
Development phase
90
Enrollment target

NCT00267332 is a Phase 3 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 90 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00267332, a Phase 3 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

TERMINATED
Registry status
Phase 3
Development phase
90 participants
Enrollment target

Study Summary

* The primary objective of this study is to evaluate the efficacy of modafinil in the treatment of opioid induced sedation as measured by the Epworth Sleepiness Scale (ESS). * The secondary objective is to estimate the frequency and severity of toxicity associated with Modafinil (400mg) in patients with opioid induced sedation.

Interventions

  • DRUG Modafinil

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2006-01
Est. Completion 2006-12
Phase Phase 3

What the Registry Record Tells You About NCT00267332

The ClinicalTrials.gov registry entry for NCT00267332 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Modafinil is the first listed.

NCT00267332 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00267332 about?

NCT00267332 is a clinical study titled "Modafinil in Opioid Induced Sedation". * The primary objective of this study is to evaluate the efficacy of modafinil in the treatment of opioid induced sedation as measured by the Epworth Sleepiness Scale (ESS). * The secondary objective is to estimate the frequency and severity of toxicity associated with Modafinil (400mg) in patients ...

What is the current status of trial NCT00267332?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2006-01. Estimated completion is 2006-12.

What interventions are being tested in trial NCT00267332?

The interventions under investigation include: Modafinil (DRUG).

Who is sponsoring clinical trial NCT00267332?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.